Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Immuneering Corporation logo

Immuneering Corporation (IMRX) Stock Ticker

NASDAQ: IMRX · Healthcare · Biotechnology
$4.16-2.58%
USD · as of 2026-09-29 · market cap $151.0M
Open IMRX in TickrDownload for iPhone

IMRX right now

62% of the float is sold short.
Options expect by Oct 6±11.8%
Options expect by Oct 29±24.4%
Priced in for Nov 11 earnings±29.2%
IV rank (30-day)4% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full IMRX picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on IMRX
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Immuneering Corporation

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.

IMRX stock facts

Ticker symbolIMRX
ExchangeNASDAQ Global Market
SectorHealthcare
IndustryBiotechnology
Market cap$151.0M
CEOBenjamin J. Zeskind
Employees57
HeadquartersCambridge, MA, US
IPO date2021-07-30
Websiteimmuneering.com

What you can see for IMRX on Tickr

Live IMRX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the IMRX report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Immuneering Corporation?

The ticker symbol for Immuneering Corporation is IMRX, listed on the NASDAQ Global Market.

What is IMRX?

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically…

HomeExploreMarketLists
All pages